Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity.
Acta Neurol Scand
; 137(4): 432-437, 2018 Apr.
Article
em En
| MEDLINE
| ID: mdl-29313881
ABSTRACT
BACKGROUND:
Cross-sensitivity of rash has been reported between various antiepileptic drugs (AEDs). However, few studies have determined the frequency and management of cross-sensitivity in patients with super-refractory status epilepticus (SRSE). AIMS OF THE STUDY To examine the optimal AED for treating SRSE with cross-sensitivity.METHODS:
We performed a retrospective review of adult patients with SRSE treated at Nagoya City University Hospital, in which we investigated the frequency of cross-sensitivity among patients with SRSE and their clinical and medical profiles.RESULTS:
We identified 10 adult patients with SRSE, 5 of whom had cross-sensitivity. Stiripentol (STP) was administered when previously used AEDs had demonstrated cross-sensitivity and failed to control seizures. After initiation of STP, the dose of general anaesthetics was reduced, and status epilepticus (SE) eventually ceased with co-administered AEDs without additional adverse effects. The mean time to SE cessation after initiation of STP was 30.8 days (range, 18-46 days), mean duration of general anaesthesia was 101.2 days (range, 74-128 days), and mean number of AEDs was 9.0 (range, 6-11).CONCLUSIONS:
This study suggests that cross-sensitivity between AEDs is common in adults with SRSE and that STP may be useful for treating SRSE with cross-sensitivity.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Estado Epiléptico
/
Toxidermias
/
Dioxolanos
/
Anticonvulsivantes
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Acta Neurol Scand
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Japão